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The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with
advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n¼147) with stage IV
NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110mgm
 2, day 1 and
100mgm
 2, day 8) and cisplatin (80mgm
 2, day 8) (IC; n¼74) or CDDP (80mgm
 2, day 1) (C; n¼73) every 3 weeks. Patients
treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P¼0.933). The 1-year survival rate was 34.3% for
IC-treated patients and 31.7% for C-treated patients. Cox’s regression analysis revealed that response to treatment (hazard ratio
(HR)¼2.787; 95% confidence interval (CI): 1.1578–4.922) and performance status (HR¼1.865; 95% CI: 1.199–2.872) was
independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8–32.2%) for IC-treated patients and 7.0%
(95% CI: 1.15–13.6%) for C-treated patients (P¼0.012); tumour growth control (partial remission (PR)þstable disease (SD)) was
observed in 26 (38%) IC and 25 (36%) C patients (P¼0.878). There was no difference in terms of quality of life between the two
chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly
higher in the IC- than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The
IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated
with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate.
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The use of front-line chemotherapy in the treatment of advanced
non-small-cell lung cancer (NSCLC) has been expanded as a result
of its increased use in the context of multimodality treatment for
stage IIIA and IIIB disease (Belani, 1993; Lilenbaum and Green,
1993; Bunn and Kelly, 1998; Webb and O’Brien, 1998) and the
development of new active drugs in both chemotherapy-naı ¨ve and
pretreated patients (Fossella et al, 1997; Androulakis et al, 1998;
Ferrigno and Buccheri, 2000; Huisman et al, 2000; Iaffaiolli et al,
2000). This increased the interest in second-line chemotherapy for
good performance status (PS) patients with NSCLC. Indeed, two
randomised studies clearly demonstrated that second-line treat-
ment with docetaxel conferred a statistically significant survival
benefit, improved quality of life and clinical benefit over either
best supportive care (Shepherd et al, 2000) or monotherapy with
either vinorelbine or ifosfamide (Fossella et al, 2000). In addition,
premetrexed administration in the second-line setting in patients
with NSCLC resulted in equivalent efficacy compared with
docetaxel but with a better toxicity profile (Hanna et al, 2004).
Moreover, the tyrosine kinase inhibitor of the epidermal growth
factor receptor, erlotinib (Tarceva), showed a progression-free and
overall survival benefit over placebo when it was administered as
second- or third-line treatment (Shepherd et al, 2004).
Since platinum-based chemotherapy still remains the most
commonly used standard of care for patients with advanced
NSCLC, the majority of studies of second-line chemotherapy have
targeted a patient population that has received front-line platinum-
based chemotherapy. However, front-line nonplatinum-based
regimens, with their favourable toxicity profile, show similar
activity in terms of overall response rate, response duration, time
to tumour progression (TTP) and overall survival as platinum-based
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scombinations (Yamamoto et al, 2000; Chen et al, 2001; Georgoulias
et al, 2001, 2005; Giaccone et al, 2002; Gridelli et al, 2002;
Kosmidis et al, 2002). Therefore, the number of patients treated
with nonplatinum combinations in the first-line setting is
increasing, and it would be of interest to develop salvage
chemotherapy regimens for this particular group of patients.
Irinotecan (CPT-11) is a semisynthetic derivative of the plant
alkaloid, camptothecin. Irinotecan appears to exert its antineo-
plastic activity via the inhibition of the nuclear enzyme
topoisomerase I, and phase II studies have shown that the drug
is active in NSCLC (Boisseau et al, 1996; O’Reilly and Rowinski,
1996). An additive or synergistic effect for the combination of
irinotecan and cisplatin (CDDP) has also been described (Kano
et al, 1992; Kudoh et al, 1993). Early phase I and II studies
demonstrated that the combination of irinotecan and cisplatin is
active in chemotherapy-naı ¨ve patients with NSCLC, achieving
response rates up to 50% (Masuda et al, 1992, 1993; Mori et al,
1997; Ueoka et al, 1999; Wagner et al, 1999; Kakolyris et al, 2000).
Moreover, the combination of irinotecan and cisplatin resulted in
an objective response rate (ORR) ranging from 22 to 29% and a
median survival time of 8 months in both platinum-refractory
patients with advanced NSCLC (Nakanishi et al, 1999) and patients
who were previously treated with a taxane/gemcitabine regimen
(Kakolyris et al, 2001). The main toxicities were severe neutro-
penia, diarrhoea and fatigue (Kakolyris et al, 2001).
Based on the promising activity of irinotecan/cisplatin combi-
nation in our phase I (Kakolyris et al, 2000) and II (Kakolyris et al,
2001) studies, we decided to conduct a prospective, multicentre,
randomised phase III study to compare the efficacy and tolerance
of this regimen vs single agent cisplatin in platinum-naı ¨ve patients
with advanced NSCLC pretreated with a taxane/gemcitabine
regimen.
PATIENTS AND METHODS
Patients
Patients (aged 418 years) with a World Health Organisation
(WHO) PS of 0–2 and histologically or cytologically confirmed
stage IIIB or IV NSCLC were enrolled into this trial. Additional
inclusion criteria were as follows: prior chemotherapy with a
taxane/gemcitabine-based regimen in the first-line setting; at least
one bidimensionally measurable lesion outside an irradiation field;
absence of a second primary tumour, except for basal cell
carcinoma of the skin or carcinoma in situ of the cervix; adequate
bone marrow, kidney and liver functions (with the exception of
alkaline phosphatase, which could be up to five times the UNL in
case of liver metastases); and a negative pregnancy test in women
of childbearing age. Prior radiotherapy was allowed, provided that
it had been completed at least 4 weeks prior to enrolment and
p25% of the total bone marrow had been irradiated. At least 4
weeks had to have elapsed from completion of the last cycle of
front-line chemotherapy. Patients were excluded if they had
clinically uncontrolled brain metastases or peripheral neuropathy
greater than WHO grade 1. Other exclusion criteria were as
follows: severe cardiopulmonary insufficiency, severe angina
pectoris or myocardial infraction within 6 months prior to study
entry, active infection, severe malnutrition (loss of 415% of body
weight) or a life expectancy of o3 months. The trial has been
approved by the Ethics and Scientific Committees of the
participating Institutions and all patients had to sign written
informed consent in order to participate in the study.
Treatment plan and dose modifications
Patients were centrally registered and eligible patients were
stratified according to their PS and the stage of the disease.
Patients were randomised to receive either irinotecan (Campo;
CPT-11, Aventis Pharma, Antony, France) at the dose of 110 and
100mgm
 2 on days 1 and 8 (Kakolyris et al, 2000, 2001),
respectively, and cisplatin (Platinol; CDDP, Bristol Meyers Squibb,
Princeton, NJ, USA) at the dose of 80mgm
 2 on day 8 (IC arm) or
cisplatin at the same dose on day 1 (C arm). Standard hydration
and forced diuresis were used for the administration of cisplatin.
In both arms, cycles were repeated every 3 weeks. Three
chemotherapy cycles were administered followed by three addi-
tional cycles in case of objective response or stable disease;
treatment was discontinued in case of progressive disease or
intolerable toxicity. All patients received standard antiemetic
therapy with odansteron 16mg and dexamethasone 8mg given
intravenously (i.v.) 30min prior to chemotherapy administration.
Loperamide was used for the treatment of delayed diarrhoea due to
irinotecan, according to the manufacturer’s instructions.
Dose modifications were performed according to the haemato-
logic toxicity and diarrhoea. Patients developing grade 3 and 4
neutropenia without fever received the subsequent cycles with
prophylactic recombinant human/granulocyte colony-stimulating
factor (rhG-CSF: Granocyte, Aventis Pharma) at the dose of
150mgm
 2 from day 9 to day 15, in order to maintain a reasonable
dose intensity. In case of persistent neutropenia despite the
prophylactic use of rhG-CSF administration or in case of febrile
neutropenia (fever more than 37.51C for at least 24h), the day 8
doses of both drugs were reduced by 25% in all subsequent cycles.
In case of grade 3 or 4 delayed diarrhoea, all subsequent cycles
were administered with a 25% reduction of the irinotecan dose.
Patients requiring more than one dose reduction were withdrawn
from the study.
Baseline and follow-up assessments
Baseline assessments included complete medical history and
physical examination, complete blood cell count with differential
and serum chemistry. Bidimensionally measurable disease was
determined by standard imaging procedures at baseline (chest
X-ray, CT scans of the thorax, abdomen and brain and whole-body
bone scan). Abdominal ultrasonography and magnetic resonance
imaging scans were performed if indicated. Follow-up brain CT
scans and liver or adrenal ultrasound exams were performed at the
discretion of the treating physician. Tumour assessment for
response was performed every three chemotherapy cycles.
Complete medical history and physical examination, as well as
complete blood cell count with differential and serum chemistry
were performed every 3 weeks. Treatment-related haematologic
toxicity was evaluated weekly, and daily in patients with grade 3
and 4 neutropenia, febrile neutropenia or thrombocytopenia.
For the quality of life assessment, the Lung Cancer Symptom
Scale (LCSS) and the EuroQOL (EQ-5D) questionnaire were used
at baseline and every three chemotherapy cycles thereafter (Hollen
et al, 1993; Rabin and de Charro, 2001).
Patients who received at least three cycles of chemotherapy were
assessed for response according to WHO criteria (World Health
Organization, 1979). All responses had to be maintained for at
least 4 weeks and were confirmed by an independent panel of
radiologists. Patients who received at least one chemotherapy
cycle were assessed for toxicity. The standard WHO criteria were
used for the evaluation of toxicity (World Health Organization,
1979).
Statistical considerations
This was a prospective, multicentre, randomised phase II trial. The
primary end point was the comparison of median survival times.
Secondary end points included objective tumour response rates,
duration of response, TTP, treatment tolerance and quality of life.
For the sample size calculation, the primary outcome measure was
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ssurvival time: 8 months for the IC group and 4 months for C
group. In all, 65 patients/arm were required for the study to
demonstrate a significant difference (at the 5% level) between the
two survival curves with a power of 90%.
Differences of rates between groups were assessed by Pearson’s
w
2 test or Fisher’s test where appropriate. Time-to-event end points
were calculated using Kaplan–Meier methods with appropriate
censoring. The independent influence of several factors on the risk
of nonresponse, relapse or nonsurvival was assessed by logistic
regression, while that on the hazards of relapse or failure of
survival by Cox’s proportional-hazards model (Collet, 1999;
Tangent and Koch, 1999). Survival was calculated from the date
of randomisation until the date of death. TTP was assessed from
the date of randomisation until the date of disease progression.
Response duration was calculated from the date that the criteria of
response were met for the first time until the date of documenta-
tion of disease progression.
RESULTS
Patients’ demographics
From August 1999 to August 2002, 147 pretreated patients with
NSCLC were registered and randomised to receive either IC
(n¼74) or C (n¼73). Most of the patients (85%) had received
front-line chemotherapy with docetaxel and gemcitabine in the
context clinical trials conducted by the Hellenic Oncology
Research Group (HORG); 15% of the patients had received a
combination of paclitaxel/gemcitabine in the first-line setting.
Three patients in IC (one did not fulfil the inclusion criteria and
two had never received treatment) and five patients in C (one had a
second primary tumour and four had never received treatment)
were not evaluable. Table 1 demonstrates patient characteristics.
The median age was 64 and 68 years for IC and C, respectively.
The two groups were well balanced with respect to gender, PS,
histology and extension of the disease (with a median number of
two involved organs/patient) as well as the pretreatment disease
parameters. All patients in both arms had stage IV disease. The
median interval time from the last chemotherapy cycle was 1.4
(range, 1–27.7) and 2.9 months (range, 1–54) in the IC and C
arms, respectively; in addition, 52 (73%) and 35 (53%) patients
enrolled in the IC and C arms, respectively, had resistant or
refractory disease. In all, 20 (28%) and 13 (19%) of IC- and C-
treated patients, respectively, received third-line chemotherapy,
which mainly consisted of single agent vinorelbine (n¼8 patients
in both groups), gemcitabine (n¼10 patients), gefitinib (n¼5
patients), topotecan (n¼5 patients) or other regimens off
protocol.
Survival
The median survival times were 7.8. (range, 0.5–25.2) and 8.8
(range, 0.5–23.3) months in patients treated with IC and C,
respectively (log-rank test: P¼0.934) (Figure 1). The 1-year
survival rates were 34.3 and 31.7% in IC and C arms, respectively.
Survival was not affected by age, gender, histology and the number
of tumour sites involved. Conversely, responders to second-line
treatment had significantly better survival time (median 17.0
months; range, 4–25.2) than those who failed to respond (median
7.6 months; range, 0.5–23.8) (P¼0.0001). Moreover, the survival
time was significantly better in patients with PS of 0–1 (median 9.4
months; range, 0.5–25.2) than those with PS of 2 (median 4.5
months; range, 1.0–22.3) (P¼0.006). Both effects were indepen-
dent of the regimen used. Cox’s regression analysis confirmed that
these two factors had an independent effect on the hazard of death.
The risk of death for nonresponders to chemotherapy was about
three times higher than that of responders (hazard ratio
(HR)¼2.787; 95% confidence interval (CI) 1.578–4.922); similarly,
the risk of death of patients with a PS of 2 was about two times
higher than that of patients with PS of 0–1 (HR¼1.865, 95% CI
1.199–2.872) (P¼0.005).
Table 1 Patient characteristics
IC group C group
n % n %
Patients enrolled 74 73
Patients eligible and evaluable for
response and toxicity
71 96 68 93
Age (years)
Median (range) 61 (36–77) 64 (36–78)
Gender
Male 64 90 58 85
Female 7 10 10 15
Stage
I I I ————
IV 74 100 73 100
PS (WHO)
0 – 1 5 88 2 5 37 8
2 1 31 8 1 52 2
Histology
Squamous 26 37 24 35
Adenocarcinoma 33 47 33 49
Large cell 1 1 1 1
Undifferentiated 11 15 10 15
Prior treatment
Surgery 13 18 9 13
Radiotherapy (adjuvant/curative) 12 17 11 16
Chemotherapy 74 100 68 100
Line of chemotherapy
Second 68 96 61 90
Third 3 4 7 10
Objective response to first-line chemotherapy
CR — — 1 2
PR 17 24 22 32
SD 18 25 26 38
PD 36 51 19 28
PS¼performance status; WHO¼World Health Organisation; CR¼complete
remission; PR¼partial remission; SD¼stable disease; PD¼progressive disease.
Months
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Figure 1 Kaplan–Meier survival curves of patients treated with IC and C
regimens.
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sThe median follow-up period was 7.0 (range, 0.5–25) and 6.5
(range, 0.5–23) months for IC and C patients, respectively
(P¼0.580). During this period, 61 (85.9%) IC-treated patients
and 52 (76.5%) C-treated patients died (P¼0.153). In the IC arm,
the causes of death were as follows: disease progression (n¼58);
lower respiratory infection and septicaemia leading to acute renal
failure (n¼1); cardiorespiratory failure (n¼1); and ventricular
arrhythmia probably due to myocardial ischaemia (n¼1). In the C
arm, the reason of death was disease progression (n¼52).
Response to treatment
Seven patients in the IC and six in the C arm were lost to follow-up
and were considered as progressors in the intention-to-treat
analysis. There were no complete responses in either chemo-
therapy arm. In all, 16 (22.5%; 95% CI: 12.8–32.2%) patients in
IC arm and five (7%; 95% CI: 1.15–13.6%) in C arm had a partial
response (P¼0.012). Stable disease was observed in 11 (15.5%)
and progressive disease in 44 (62%) IC patients; similarly, stable
and progressive disease was documented in 20 (29%) and 43 (63%)
patients in the C arm, respectively. The tumour growth control rate
(complete remission (CR)þpartial remission (PR)þstable disease
(SD)) was 38% in the IC arm and 36% in the C arm (Fisher’s exact
test; P¼0.878). In all, 11 (20%) IC-treated patients and two (4%)
C-treated patients who responded to second-line chemotherapy
had failed to respond to front-line chemotherapy; moreover, the
IC regimen resulted in an almost three-fold higher incidence of
objective responses compared with the C regimen in patients with
sensitive (ORR: 21 vs 6%, respectively; P¼0.113) or resistant/
refractory (23 vs 8%, respectively; P¼0.071) disease. The
incidence of objectively validated response in lesions located in
the lung or lymph nodes was significantly higher in patients
treated with IC than with C (ORR: 23 vs 8%, P¼0.012 for lung and
ORR: 28 vs 7%, P¼0.012 for lymph nodes); there was no difference
in the ORRs for lesions located in the liver (13 vs 9%; P¼0.738),
pleura (27 vs 13%; 0¼0197) or adrenal (14 vs 0%; P¼0.242).
Response was significantly affected by PS, since 15 (26%) and three
(6%) patients with PS of 0 and 1 treated with IC and C,
respectively, achieved an objective response (P¼0.004). The risk
of nonresponse for patients with PS 0 and 1 in group C was almost
six times higher than that of patients with the same PS in the
IC group (odds ratio (OR): 5.814; 95% CI: 1.577–21.438). The
treatment regimen was revealed to be the only independent
predictive factor for response (P¼0.017) (OR¼3.665; 95% CI:
1.261–10.656). The median duration of response was 6 months
(range, 2.1–17.8) in IC-treated patients and 12 months (range,
2.3–12.2) in C-treated patients (log-rank test: P¼0.154). The
median TTP was 2.6 (range, 1–20.3) and 2.1 (range, 1–17.6)
months in the IC and C arms, respectively (log-rank test;
P¼0.641); the 1-year progression-free survival rates were 6.4
and 10.9% in the IC and C arms, respectively.
Compliance with the treatment
A total of 247 IC (median three cycles/patient (range, 1–9)) and 243
C cycles (median three cycles/patient (range, 1–6)) were adminis-
tered. The median interval between cycles was 23 days (range,
21–37) in the IC and 21 days (range, 21–27) in C arm. The median
dose intensity for patients randomised to IC was 56mgm
 2week
 1
(range, 29–70) for irinotecan and 22mgm
 2week
 1 (range 9–27)
for cisplatin corresponding to 80 and 81% of the protocol planned
doses, respectively. The median dose intensity of cisplatin
in patients randomised to arm C was 26.6mgm
 2week
 1 (range,
19–27), which corresponded to 99% of the planned dose.
In all, 77 (31%) and 30 (12%) cycles were delayed in IC and C
arms, respectively (P¼0.0001). A total of 49 (20%) IC and 10 (4%)
C cycles were delayed more than 7 days (P¼0.005). The reasons
for treatment delay were as follows: haematological toxicity (IC
arm: n¼24 cycles; C arm: n¼8 cycles; P¼0.004); nonhaemato-
logical toxicity (IC arm: n¼12 cycles; C arm: n¼1 cycle;
P¼0.002); both haematologic and nonhaematologic (IC arm:
n¼1 cycle; C arm: n¼0 cycles); and finally, for reasons unrelated
to treatment or disease (40 IC and 21 C cycles).
In all, 52 (21%) IC and four (2%) C cycles, respectively, required
dose reductions (P¼0.0001). The reasons for dose reduction were
as follows: haematological toxicity (IC arm: n¼11 cycles; C arm:
n¼0 cycles); nonhaematological toxicity (IC arm: n¼19 cycles; C
arm: n¼3 cycles); both haematological and nonhaematological
toxicity (IC arm: n¼4 cycles; C arm: n¼0 cycles); and for reasons
unrelated to disease or treatment (IC arm: n¼16 cycles; C arm:
n¼1 cycle).
Toxicity
The haematological and nonhaematological toxicities are sum-
marised in Table 2. Grade 3 and 4 neutropenia occurred in 22
(31%) and three (4%) patients in IC and C arms, respectively
(P¼0.001). A total of 128 (52%) and 94 (39%) cycles in IC and C,
respectively, required prophylactic rhG-CSF support (P¼0.001).
Five (7.0%) patients treated with IC developed febrile neutropenia.
All were hospitalised and uneventfully recovered following
treatment with i.v. broad-spectrum antibiotics and rhG-CSF
support. There was no case of febrile neutropenia in patients
treated with C. Grade 2–4 anaemia was observed in 27 (38%) IC
and 20 (30%) C patients (P¼0.283). Five (7%) patients in the IC
and two (3%) patients in the C arm developed grade 3 and 4
Table 2 Haematologic and nonhaematologic toxicity of second-line IC and C
Grade 1 Grade 2 Grade 3 Grade 4
IC C IC C IC C IC C
Anaemia 38 (54) 35 (52) 23 (32) 19 (28) 4 (6) — — 1 (2)
a
Neutropenia 11 (16) 9 (13) 13 (18) 7 (10) 12 (17) 3 (4) 10 (14)
b —
Thrombocytopenia 18 (25) 12 (18) 3 (4) 1 (2) 3 (4) 2 (3) 2 (3) —
Nausea/vomiting 11 (16) 4 (6) 18 (25) 13 (19) 8 (11) 3 (4) 1 (1)
c —
Diarrhoea 8 (11) 3 (4) 16 (23) 2 (3) 14 (20) 1 (2) 5 (7)
d 1 (2)
Mucositis 2 (3) 2 (3) — — — — — 1 (2)
Neurotoxicity 2 (3) 4 (6) 3 (4) 3 (4) — 1 (2) — —
Asthenia 19 (27) 8 (12) 13 (18) 12 (18) 8 (11) 7 (10) — 2 (3)
Fluid retention syndrome 2 (3) — 2 (3) 1 (2) — 1 (2) 1 (1) 1 (2)
Non-neutropenic infection 9 (13) 6 (9) — — — — — 1 (2)
The results are expressed as the ‘number of patients’. In parentheses: % of patients.
aGrade 2–4 anaemia; P¼0.283.
bGrade 3 and 4 neutropenia; P¼0.001.
cGrade 3 and 4
nausea/vomiting; P¼0.083.
dGrade 3 and 4 diarrhoea; P¼0.0001.
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sthrombocytopenia (P¼0.269). No patient developed bleeding
episodes requiring platelet transfusions or hospitalisation.
The nonhaematological toxicity was relatively mild. Grade 3 and
4 nausea/vomiting was reported by nine (13%) IC and three (4%) C
patients. There was a significantly higher incidence of grade 3
and 4 diarrhoea in patients treated with IC (n¼19; 27%) than in
those treated with C (n¼2; 4%) (P¼0.0001); hospitalisation was
required in 15 out of 19 IC (median duration of hospitalisation: 6
days) and in two out of two C patients with grade 3 and 4
diarrhoea. All patients recovered. Grade 2–4 asthenia was reported
by 21 (30%) IC and 21 (31%) C patients. Other toxicities were mild.
The toxicity profile of IC and C was not modified by patients’ PS.
Grade 3 and 4 neutropenia and diarrhoea remained the most
serious adverse events associated with the IC regimen in patients
with either PS of 0–1 or 2 (Table 3).
Symptom and quality of life assessment
Patients’ compliance with quality of life assessment for IC group
was 98% at baseline, 73% at the third cycle and decreased to
31% at the end of chemotherapy (EoC). Similarly for the C group,
compliance was 100, 75 and 30%, respectively. Disease-related
symptoms revealed no significant differences between the two
arms at baseline and during treatment (at third cycle and EoC).
Patients treated with IC reported no significant differences
between baseline and EoC assessment. Similarly, no significant
differences were observed for C group, while a trend towards
improvement was observed for cough (P¼0.069).
DISCUSSION
The present multicentre, randomised phase II study was designed
in order to evaluate the role of platinum-based chemotherapy as
second-line treatment in patients with advanced NSCLC who
have received first-line chemotherapy with a taxane/gemcitabine
regimen. The results demonstrate that although the combination of
irinotecan/cisplatin resulted in a significantly higher response rate
than cisplatin monotherapy, there was no difference between the
two chemotherapy arms in terms of 1-year survival, median overall
survival, duration of response and TTP. However, it should be
stressed that our findings should not be generalised for patients
treated with other than taxane/gemcitabine nonplatinum-contain-
ing regimens in the first-line setting.
There are very few data in the literature concerning the role of
platinum compounds in the second-line setting in patients with
advanced NSCLC. This may be due to the consideration of platinum-
based combinations as ‘gold standard treatment’ for the front-line
setting; moreover, the cumulative neurotoxicity of cisplatin may
preclude further treatment with this agent after failure of a front-line
platinum-based regimen. In the present study, we demonstrated that
second-line treatment with either irinotecan (CPT-11) plus cisplatin
(IC) or cisplatin (C) alone in patients pretreated with taxanes and
gemcitabine could confer a similar overall median survival (7.8 and
8.8 months, respectively). This should be attributed to the fact that
both regimens resulted in a similar tumour growth control rate (38
and 36% for IC and C regimens, respectively). The Cox regression
analysis demonstrated that response to chemotherapy (CRþPR)
and PS (0–1) were independent prognostic factors for survival,
irrespectively of the chemotherapy regimen. It is interesting to note
that second-line cisplatin resulted in a median overall survival of 8.8
months, while second-line docetaxel and premetrexed in 7.5 and 8.3
months, respectively (Fossella et al, 2000; Shepherd et al,2 0 0 0 ;
Hanna et al, 2004).
The low antitumour activity (ORR¼7%) of CDDP in our
patients is in agreement with previous reports demonstrating
responses of less than 10% (Belani, 1998). Conversely, the
irinotecan/cisplatin combination resulted in a significantly higher
ORR (¼22.5%) confirming our previous observation (Kakolyris
et al, 2001). Similarly, a 31% response rate was observed
(Nakanishi et al, 1999) with a weekly administration of irinotecan
and cisplatin in 16 patients with refractory NSCLC. A recent
multicenter, randomised phase II study, which compared the
irinotecan/gemcitabine combination vs irinotecan in NSCLC
patients pretreated with taxanes plus cisplatinum, demonstrated a
poor antitumour activity of irinotecan (ORR¼4.2%) (Georgoulias
et al, 2004) as already reported by Negoro et al (see Ferrigno
and Buccheri, 2000). Taken together, the improved antitumour
activity of irinotecan/cisplatin combination (Nakanishi et al,
1999; Kakolyris et al, 2001) and the poor activity of single agent
irinotecan or cisplatin in the second-line setting seem to indicate
an in vivo synergism between the two agents as it has been shown
in preclinical studies (Kano et al, 1992; Kudoh et al, 1993).
The irinotecan/cisplatin regimen was active in patients failing to
respond to front-line taxane/gemcitabine-based regimens. More-
over, this combination was equally active in both sensitive and
resistant/refractory to taxane/gemcitabine tumours. As the chemo-
sensitivity to first-line chemotherapy may influence the results
with second-line chemotherapy, one should consider that the
tumour growth control rates achieved with front-line treatment
were different for the two arms: 49% for the IC vs 72% for the C
arm. This imbalance has to be attributed to a selection bias of the
randomisation procedure since the patients were not stratified
according to their response to previous front-line chemotherapy.
However, logistic regression analysis revealed that only the
chemotherapy regimen was an independent predictive factor for
response. Similar results have been previously reported in phase II
studies (Kakolyris et al, 2001). Several phase II studies have also
shown that platinum-based chemotherapy regimens may be active
in the second-line setting (Gridelli et al, 1992; Stathopoulos et al,
1999; Huisman et al, 2001; De Pas et al, 2001). It is interesting to
note that despite the higher response rate achieved with IC, there
was no difference in terms of quality of life between IC and C. We
do not have a clear explanation for this observation, although we
cannot exclude that it may be due to the similar tumour growth
control rate achieved by the two regimens.
Table 3 Grade 3 and 4 haematologic and nonhaematologic toxicities according to PS
PS 0 and 1 PS 2
Toxicity CPT-11/CDDP (n¼56) CDDP (n¼52) P-value CPT-11/CDDP (n¼15) CDDP (n¼16) P-value
Anaemia
a 17 (30.3%) 14 (26.9%) 0.693 10 (66.7%) 6 (37.6%) 0.104
Neutropenia 15 (26.8%) 3 (5.8%) 0.011 9 (59.7) — 0.0001
Thrombocytopenia 3 (5.4%) 1 (2.0%) 0.345 2 (13%) 1 (6.3%) 0.505
Febrile neutropenia 4 (7.2%) — 0.169 1 (6.7%) — 0.294
Nausea/vomiting 5 (9.0%) 1 (2.0%) 0.112 4 (26.7%) 2 (12.5%) 0.318
Diarrhoea 12 (21.6%) — 0.0001 7 (46.7%) 2 (12.5%) 0.036
Asthenia
a 13 (23.2%) 16 (30.7%) 0.202 8 (53%) 5 (31.4%) 0.372
PS¼performance status.
aGrade 2–4.
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treatment. Therefore, chemotherapy regimens used in this setting
should lack severe toxicity in the interest of patients’ quality of life.
The chemotherapy regimens used in the present study displayed a
manageable toxicity profile and there was no treatment-related
death. However, the irinotecan/cisplatin regimen was associated
with a significantly higher incidence of grade 3 and 4 neutropenia
and neutropenic fever than cisplatin monotherapy, leading to a
higher proportion of patients requiring prophylactic use of G-CSF.
The IC regimen was also associated with a higher incidence of
grade 3 and 4 diarrhoea than single agent cisplatin; this adverse
event necessitated patients’ hospitalisation for administration of
i.v. broad-spectrum antibiotics and hydration. Although a
pharmacoeconomic evaluation of the two regimens was not
performed, it is obvious that these two main toxicities of the IC
regimen required patient hospitalisation, which is not without
economic consequences. This is an important issue, especially
when taking into account the similar overall survival achieved by
the two chemotherapy regimens and the more favourable toxicity
profile of cisplatin monotherapy.
In conclusion, our observations indicate that second-line CDDP
is equally effective in terms of overall survival, TTP and quality of
life as the irinotecan/CDDP regimen in patients with advanced
NSCLC pretreated with a taxane/gemcitabine front-line combina-
tion. This finding taken together with our prior observation that
single agent irinotecan given in the second-line setting resulted in
a similar overall survival of patients with NSCLC as the irinotecan/
gemcitabine combination (Agelaki et al, 2001) raise the question of
whether monotherapy is, indeed, a sufficient second-line treatment
of NSCLC. However, additional studies evaluating different doses
and/or administration schedules as well as novel agent combina-
tions are needed to further elucidate the value of second-line
chemotherapy in patients with advanced NSCLC.
ACKNOWLEDGEMENTS
This work was partially supported by an investigational grant from
the Cretan Association for Biomedical Research (CABR).
REFERENCES
Agelaki S, Bania H, Kouroussis Ch, Blazoyiannakis G, Souglakos J, Tsiafaki
X, Kalbakis K, Rapti A, Androulakis N, Georgoulias V, Papadakis E
(2001) Second-line treatment with vinorelbine and carboplatin in
patients with advanced non-small cell lung cancer. A multicenter phase
II study. Lung Cancer 34(Suppl 4): 77–80
Androulakis N, Kouroussis CH, Kakolyris S, Tzannes S, Papadakis E,
Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I,
Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulias V
(1998) Salvage treatment with paclitaxel and gemcitabine for patients
with non-small cell lung cancer after cisplatin- or docetaxel-based
chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127–1130
Belani CP (1993) Multimodality management of regionally advanced non-
small cell lung cancer. Semin Onco 20: 302–314
Belani CP (1998) Single agents in the second-line treatment of non-small
cell lung cancer. Semin Oncol 25(3, Suppl 8): 10–14
Boisseau M, Guichard S, Canal P (1996) Irinotecan (CPT-11): current status
and perspectives. Exp Opin Invest Drugs 5: 613–626
Bunn PA, Kelly K (1998) New chemotherapeutic agents prolong survival
and improve quality of life in non-small cell lung cancer: a review of the
literature and future directions. Clin Cancer Res 4: 1087–1100
Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, Whang-Peng J
(2001) A phase II randomized trial of paclitaxel plus carboplatin (PC) or
paclitaxel plus gemcitabine (PG) in inoperable, chemonaive non-small
cell lung cancer (NSCLC). Am Soc Clin Oncol 20: 340a (abstract 1358)
Collet D (1999) Modeling Survival Data in Medical Research. London, UK:
Chapman & Hall
De Pas T, de Braud F, Mandala M, Curigliano G, Catania C, Ferretti G, Sozzi
P, Solli P, Goldhirsch A (2001) Cisplatin and vinorelbine as second-line
chemotherapy in patients with advanced non-small cell lung cancer
resistant to taxol plus gemcitabine. Lung Cancer 31: 267–270
Ferrigno D, Buccheri G (2000) Second-line chemotherapy for recurrent
non-small cell lung cancer: do new agents make a difference? Lung
Cancer 29: 91–104
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman
L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim
Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of
docetaxel vs vinorelbine or ifosfamide in patients with advanced non-
small cell lung cancer previously treated with platinum-containing
regimens. J Clin Oncol 18: 2354–2362
Fossella FV, Lee JS, Hong WK (1997) Management strategies for recurrent
non-small cell lung cancer. Semin Oncol 24: 455–462
Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P,
Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N,
Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N,
Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin vs docetaxel
plus gemcitabine in advanced non-small-cell lung cancer: a phase III
randomized trial. J Clin Oncol 23: 2937–2945
Georgoulias V, Kouroussis Ch, Agelidou A, Boukovinas J, Palamidas Ph,
Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A,
Tselepatiotis E, Vlachonikolis I (2004) Irinotecan plus gemcitabine vs
irinotecan for the second-line treatment of patients with advanced non-
small cell lung cancer pretreated with docetaxel and cisplatin : A
multicenter, randomized, phase II study. Br J Cancer 91: 482–488
Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes
M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-
platinum-based chemotherapy in advanced non-small cell lung cancer: a
randomized multicentre trial. Lancet 357: 1478–1484
Giaccone G, on behalf of the EORTC Group (2002) Early results of a
randomized phase III trial of platinum-containing doublets vs a non-
platinum doublet in the treatment of advanced non-small cell lung
cancer: European Organization for Research and Treatment of Cancer
08975. Sem Oncol 29(Suppl 9): 47–49
Gridelli C, Airoma G, Incoronato P, Pepe R, Palazzolo G, Rossi A, Bianco
AR (1992) Mitomycin C plus vindesine or cisplatin plus epirubicin in
previously treated patients with symptomatic advanced non-small cell
lung cancer. Cancer Chemother Pharmacol 30: 212–214
Gridelli C, Shepherd F, Perrone F, Illiano A, Piantedosi FV, Robbiati SF,
Manzione L, Barbera S, Frontini L, Veltri E, Cigolari S, Findlay BP, Hirsh
V, Seymour L, Bezjak A, Gallo C (2002) Gemvin III: A phase III study of
gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinor-
elbine or gemcitabine chemotherapy (PCT) for stage IIIb or IV non-small
cell lung cancer (NSCLC): an Italo-Canadian study. Proc Am Soc Clin
Oncol 21: 292a (abstract 1165)
Hanna N, Shpherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J,
Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K,
Gervais R, Shanaryar J, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn
Jr PA (2004) Randomized phase III trial of premetrexed vs docetaxel in
patients with non-small cell lung cancer previously treated with
chemotherapy. J Clin Oncol 22: 1589–1597
Hollen PJ, Gralla RJ, Kriss MG, Eberly SW, Cox C (1993) Quality of life
assessment in individuals with lung cancer: testing the Lung Cancer
Symptom Scale (LCSS). Eur H Cancer 29A(Suppl 1): S51–S58
Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF
(2001) Accelerated cisplatin and high-dose epirubicin with G-CSF
support in patients with relapsed non-small cell lung cancer: feasibility
and efficacy. Br J Cancer 16: 1456–1461
Huisman C, Smit EFR, Giaccone G, Postus PE (2000) Second-line
chemotherapy in relapsing or refractory non-small cell lung cancer: a
review. J Clin Oncol 18: 3722–3730
Iaffaiolli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S, Griffo
S, Gentile M, Fraioli G, Frattolillo A, Muto P, Libutti M, De Marino V,
Illiano A, Barbarisi A (2000) Phase I–II study of gemcitabine and
paclitaxel in pretreated patients with stage IIIB–IV non-small cell lung
cancer. Lung Cancer 30: 203–210
CDDP with or without CPT-11 as second-line treatment in NSCLC
V Georgoulias et al
768
British Journal of Cancer (2005) 93(7), 763–769 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sKakolyris S, Kouroussis Ch, Souglakos J, Agelaki S, Kalbakis K, Vardakis N,
Vamvakas L, Georgoulias V (2001) Cisplatin and irinotecan (CPT-11) as
second-line treatment in patients with advanced non-small cell lung
cancer. Lung Cancer 34: S71–S76
Kakolyris S, Souglakos J, Agelaki S, Kourousis CH, Mavroudis D, Sarra E,
Malliotakis P, Georgoulias V (2000) A dose-escalation study of irinotecan
(CPT-11) in combination with cisplatin in patients with advanced non-
small cell lung cancer previously treated with a docetaxel-based front-
line chemotherapy. Lung Cancer 30: 193–198
Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S,
Miura Y (1992) Effects of CPT-11 in combination with other anticancer
agents in culture. Int J Cancer 50: 604–610
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E,
Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D,
Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus
carboplatin vs gemcitabine plus paclitaxel in advanced non-small cell
lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578–3585
Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro
S, Matsui K, Takifuji N, Morino H (1993) Enhanced antitumour efficacy
of a combination of CPT-11, a new derivative of camptothecin, and
cisplatin against lung tumour xenografts. Jpn J Cancer Res 84: 203–207
Lilenbaum R, Green M (1993) Novel chemotherapeutic agents in the
treatment of non-small cell lung cancer. J Clin Oncol 1: 1391–1402
Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N,
Nakagawa K, Tamanoi M, Nitta T, Hirashima T (1993) Phase I and
pharmacologic study of irinotecan in combination with cisplatin for
advanced lung cancer. Br J Cancer 68: 777–782
Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S,
Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with
cisplatin for advanced non-small cell lung cancer. JC l i nO n c o l10: 1775–1780
Mori K, Hirose T, Tominaga K (1997) Phase II study of irinotecan and
infusional P with recombinant human granulocyte colony-stimulating
factor support in the treatment of advanced non-small cell lung cancer.
Proc Am Soc Clin Oncol 16: 476a (abstract 1714)
Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H, Takaki
Y, Minami T, Kawasaki M, Hara N (1999) Second-line chemotherapy
with weekly cisplatin and irinotecan in patients with refractory lung
cancer. Am J Clin Oncol 22: 399–402
O’Reilly S, Rowinski EK (1996) The clinical status of irinotecan (CPT-11), a novel
water soluble camptothecin analogue. Crit Rev Oncol Hematol 24: 47–70
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the
EuroQo Group. Ann Med 33: 337–343
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M,
Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J
(2000) Prospective randomized trial of docetaxel vs best supportive care
in patients with non-small cell lung cancer previously treated with
platinum-based chemotherapy. J Clin Oncol 18: 2095–2103
Shepherd FA, Pereira J, Cicleane TE, Tan EH, Hirsh V, Thongprasert S,
Besjak A, Tu D, Santabarbara P, Seymour L (2004) A randomized
placebo-controlled trial of erlotinib in patients with advanced non-
small cell lung cancer (NSCLC) following failure of 1st line or 2nd
line chemotherapy. A National Cancer Institute of Canada Clinical
Trials Group (NCIC) (TG) trial. Proc Am Soc Clin Oncol 22: 4
(abstract 7022)
Stathopoulos GP, Rigatos S, Malamos NA (1999) Paclitaxel combined with
cisplatinum as second-line treatment in patients with advance non-small
cell lung cancer. Oncol Rep 6: 797–800
Tangent CM, Koch GG (1999) Nonparametric analysis of covariance for
hypothesis testing with Logrank and Wilcoxon scores and survival-rate
estimation in a randomized clinical trial. J Biopharm Stat 9: 307–338
Ueoka H, Kiura K, Hiraki S, Eguchi K, Okimoto N, Harita S, Marukawa M,
Yonei T, Kamei H, Segawa Y, Shibayama T, Harada M (1999)
Fractionated administration of P and irinotecan in patients with stage
IIIB and IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol
18: 525a (abstract 2026)
Wagner H, Faderl B, Dankelmann E, Deuss B, Achterrath W, Pawel J vo
(1999) Phase II study of irinotecan in combination with cisplatin as first
line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc
Am Soc Clin Oncol 18: 527a (abstract 2032)
Webb A, O’Brien M (1998) Where to go with new expensive treatment in
NSCLC. Br J Cancer 78: 159–162
World Health Organization (1979) WHO Handbook of Reporting Results of
Cancer Treatment WHO Offset Publication, No. 48. Geneva, Switzerland:
World Health Organization
Yamamoto N, Fukuoka M, Nakagawa K, Negoro S, Matui K, Kawahara M,
Takada Y, Senba H, Kudo S, Ariyoshi Y (2000) Randomized phase II
study of docetaxel (DOC) plus cisplatin (CDDP) vs DOC plus irinotecan
in advanced non-small cell lung cancer (NSCLC): a West Japan
Thoracic Oncology Group (WJTOG) study. Ann Oncol 11(Suppl 4): 107
(abstract 4840)
Appendix A1
Participating centres and investigators
Centre Investigator
Department of Medical Oncology, University General Hospital of Heraklion, Crete V Georgoulias, N Androulakis, K Kalbakis, Ch Kouroussis, L Vamvakas,
G Samonis
1st Department of Pulmonary Diseases, ‘Sotiria’ General Hospital of Athens A Agelidou, E Papadakis
8th Department of Pulmonary Diseases, ‘Sotiria’ General Hospital of Athens O Anagnostopoulou, A Rapti, G Pavlakou, E Tsaroucha
Medical Oncology Unit, 3rd Department of Internal Medicine of University of Athens, ‘Sotiria’
General Hospital of Athens
K Syrigos
2nd Department of Medical Oncology, ‘Theagenion’ Anticancer Hospital of Thessaloniki J Stergiou, J Boukovinas, P Papakotoulas, P Markantonakis, K Dimitriadis
2nd Department of Pulmonary Diseases, ‘Papanikolaou’ Hospital of Thessaloniki N Samaras, E Mylonaki
2nd Department of Pulmonary Diseases, ‘Sismanoglion’ General Hospital of Athens F Apostolopoulou, M Agelidou, X Tsiafaki
1st Department of Pulmonary Diseases, ‘Sigmanoglion’ General Hospital of Athens P Ziotopoulos, Ph Palamidas, V Chandrinos
Department of Medical Oncology, General Hospital of Larissa A Athanasiadis
Medical Oncology Unit, Department of Propedeutic Medicine of University of Athens, ‘Laiko’
General Hospital of Athens
A Polyzos
3rd Department of Pulmonary Diseases, ‘Sotiria’ General Hospital of Athens A Christou
Department of Pulmonary Diseases of University of Athens, ‘Sotiria’ General Hospital of Athens M Veslemes
6th Department of Pulmonary Diseases, ‘Sotiria’ General Hospital of Athens M Toubis
1st Department of Medical Oncology, ‘Agios Savas’ Anticancer Hospital of Athens A Ardavanis, A Alexopoulos, G Rigatos
Department of Pulmonary Diseases, University General Hospital of Heraklion, Crete D Bouros
Department of Medical Oncology, ‘Agios Georgios’ General Hospital of Chania, Crete J Varthalitis
7th Department of Pulmonary Diseases, ‘Sotiria’ General Hospital of Athens S Tzannes, Th Grigoratou, A Geroyianni
Department of Internal Medicine, ‘Patision’ General Hospital of Athens E Tselepatiotis
1st Department of Pulmonary Diseases, ‘Papanikolaou’ General Hospital of Thessaloniki N Galanis, E Kalaitzidou
Department of Pulmonary Diseases, General Hospital of Korfu K Chainis
Department of Pulmonary Diseases, Hospital of Pulmonary Diseases of Patras J Lychros
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